4-苯基-1-(三苯基甲基)-1H-咪唑-2-甲醛 | 162537-14-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 4-苯基-1-(三苯基甲基)-1H-咪唑-2-甲醛
• 英文名称: 4-phenyl-1-(triphenylmethyl)-1H-imidazole-2-carbaldehyde
• 英文别名: 4-phenyl-1-trityl-1H-imidazole-2-carbaldehyde；4-phenyl-1-tritylimidazole-2-carbaldehyde
• CAS: 162537-14-6
• 化学式: C₂₉H₂₂N₂O
• 分子量: 414.506
• InChiKey: SUGQKQUKHXPAKE-UHFFFAOYSA-N

物化性质

• 熔点：
  184 °C(Solv: ethanol (64-17-5))
• 沸点：
  639.7±65.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-苯基-1-(三苯基甲基)-1H-咪唑-2-甲醛 在 sodium tetrahydroborate 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 6.0h， 生成 (4-phenyl-1H-imidazol-2-yl)methanol
  参考文献：
  名称：

  单环取代的咪唑类作为糖苷酶抑制剂

  摘要：

  一系列4-单取代和2,4-二取代的1 H-咪唑和1 H-咪唑-1-乙醇（RC（4）：CH 2 CH 2 Ph，CHOHCH 2 Ph，Ph或Me; RC（2）制备CH 2 OH，CHOHCH 2 OH，CN或CH 2 NHAc，并作为α-和β-葡萄糖苷酶和β-半乳糖苷酶的抑制剂进行测试。阐述了一种从4-苯基丁-1-醇开始的4-（2-苯基乙基）-1 H-咪唑的新途径。最强的抑制剂是2-取代的4-（2-苯乙基）-1 H-咪唑24a和26a（RC（2）：CH 2 OH和CHOHCH 2 OH）和2-苯基乙醇34。它们以微摩尔范围的抑制常数抑制牛肝中的β-半乳糖苷酶和解糖卡尔多氏菌中的β-葡萄糖苷酶，但不抑制啤酒酵母中的α-葡萄糖苷酶。

  DOI：

  10.1002/hlca.200590182
• 作为产物：
  描述：

  4-苯基咪唑 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 4-苯基-1-(三苯基甲基)-1H-咪唑-2-甲醛
  参考文献：
  名称：

  Synthesis, Structure, and Neuroprotective Properties of Novel Imidazolyl Nitrones

  摘要：

  A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivity imparts to the nitrone superior neuroprotective properties in vivo and in parallel reduced side effects and toxicity. Thus compound 6a (a 2-phenylimidazolyl nitrone) administered intraperitoneally protects (80%) mice from lethality induced by an intracerebroventricular administration of tert-butyl hydroperoxide (t-BHP) an oxidant capable of inducing neurodegenerative processes. Administration of the archetypal nitrone phenyl-tert-butyl nitrone (PBN) at an equimolar dose also affords some protection (60%) in this test. However, this activity is accompanied by hypothermia, whereas no such effect is apparent for 6a. Moreover, previously prepared nonsubstituted or alkyl-substituted imidazolyl nitrones were shown to be extremely toxic to rats in contrast to the compounds prepared in this study. The observed activities in vivo correlate well with the calculated partition coefficients (ClogP) and HOMO energy level.

  DOI：

  10.1021/jm991154w

文献信息

• HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Campbell John Emmerson

  公开号：US20130158003A1

  公开（公告）日：2013-06-20

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物、其合成方法、包含该化合物的药物组合物以及使用该化合物的方法。在一种实施例中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，例如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病。
• Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
  申请人：Campbell John Emmerson

  公开号：US08969349B2

  公开（公告）日：2015-03-03

  Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is R1 and R2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R11; L is —C(R6)2—C(R6)2—; B is a heteroaromatic group defined herein; and -A1-A2- , A3, R11 and R6 are defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了A-L-B式化合物及其药学上可接受的盐和立体异构体，其中A为R1和R2，与它们连接的碳原子形成一个可选择地取代一个或多个R11的1,2-苯撑环；L为—C（R6）2—C（R6）2—；B为在本文中定义的杂环芳基；-A1-A2-、A3、R11和R6在本文中定义。还披露了它们的合成方法、包含这些化合物的药物组合物以及它们的使用方法。在一个实施例中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病。
• Heteroaryl Compounds and Methods of Use Thereof
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20150166571A1

  公开（公告）日：2015-06-18

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物、它们的合成方法、包含这些化合物的药物组合物以及它们的使用方法。在一种实施方式中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，例如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病等。
• Substituted quinoxalines as PDE-10 inhibitors
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US10562916B2

  公开（公告）日：2020-02-18

  Provided herein are cyclic nucleotide phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

  本文提供了环核苷酸磷酸二酯酶抑制剂及其药物组合物，可用于治疗中枢神经系统和代谢疾病及紊乱等。
• [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2011150156A3

  公开（公告）日：2012-04-19